SUNPHARMA.NS Stock Analysis
SU
Neutral
Based on Eyestock quantitative analysis, SUNPHARMA.NS`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. The company is headquartered in Mumbai, Maharashtra and currently employs 41,000 full-time employees. The firm is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and active pharmaceutical ingredients (APIs). The company produces a comprehensive, diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. The firm's vertically integrated network enables it to produce a wide range of pharmaceuticals, including oncology, hormones, peptides, and steroidal drugs. The firm also has a product portfolio in RoW markets, including injectables, hospital products and retail products. The company offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, Yonsa, Sezaby and Sprinkle portfolio.